Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to first determine the maximum tolerated dose of capecitabine given alone or in combination with valproic acid during preoperative short-course radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal radical surgery might increase the pathologic complete tumor regression rate in patients with low-moderate risk rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma

NCT00075556

Colorectal Cancer

UNKNOWN PHASE2

Neoadjuvant Treatment for Advanced Rectal Carcinoma

NCT02551237

Rectal Carcinoma

COMPLETED PHASE3

Preoperative Radiotherapy and E7046 in Rectum Cancer

NCT03152370

Neoadjuvant Therapy in Rectal Cancer

COMPLETED PHASE1

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704

Rectal Cancer

COMPLETED PHASE2

A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer

NCT00122291

Rectal Cancer Neoplasm Metastasis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SCRT

short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.

Group Type ACTIVE_COMPARATOR

preoperative radiation therapy

Intervention Type RADIATION

25 Gy in 5 fractions over 1 week

V-SCRT

Valproic acid (V) + short course radiotherapy

Group Type ACTIVE_COMPARATOR

preoperative radiation therapy

Intervention Type RADIATION

25 Gy in 5 fractions over 1 week

Valproic Acid

Intervention Type DRUG

C-SCRT

capecitabine (C) + short course radiotherapy

Group Type ACTIVE_COMPARATOR

preoperative radiation therapy

Intervention Type RADIATION

25 Gy in 5 fractions over 1 week

Capecitabine

Intervention Type DRUG

VC-SCRT

valproic acid + capecitabine + short course radiotherapy

Group Type ACTIVE_COMPARATOR

preoperative radiation therapy

Intervention Type RADIATION

25 Gy in 5 fractions over 1 week

Valproic Acid

Intervention Type DRUG

Capecitabine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

preoperative radiation therapy

25 Gy in 5 fractions over 1 week

Intervention Type RADIATION

Valproic Acid

Intervention Type DRUG

Capecitabine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients with histologically confirmed diagnosis of adenocarcinoma of rectum falling into one of the following categories: T2N0 located at \<2 cm from anal verge T2N1 or T3N0-N1, located at \>5 cm and \<12 cm from anal verge and infiltration of perirectal fat up to a distance of 1 mm from mesorectal fascia (MRF) evaluated by MRI.

* Age ≥18 and ≤ 70
* ECOG Performance Status ≤1
* Effective contraception for both male and female patients if the risk of conception exist
* Signed written informed consent

Exclusion Criteria

* Any previous treatment for rectal cancer
* Previous pelvic radiotherapy
* Presence of metastatic disease
* Recurrent rectal tumor
* Patient with Familial Adenomatosis Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
* History of inflammatory bowel disease or active disease
* Any concurrent malignancy except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of cervix uteri. Patients with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the trial.
* Neutrophils \< 2000/mm3 or platelets \< 100.000/ mm3 or haemoglobin \<9 gr/dl.
* Creatinine levels indicating renal clearance of \<50 ml/min
* GOT and/or GPT \> 2.5 time the UNL and/or bilirubin \>1.5 time the upper-normal limits (UNL)
* Significant cardiovascular comorbidity (e.g. myocardial infarction, superior vena cava \[SVC\] syndrome, patients with an ejection fraction of \<50%) or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
* History of arrhythmia (multifocal premature ventricular contractions \[PVCs\], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia.
* Patients with long QT-syndrome or QTc interval duration \> 480 msec or concomitant medication with drugs prolonging QTc (see list in the appendix)
* Known dihydropyrimidine dehydrogenase (DPD) deficiency
* HIV positive patients
* Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
* Known or suspected hypersensitivity to any of the study drugs.
* Patient who have had prior treatment with an HDAC inhibitor and patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid.
* Concurrent uncontrolled medical conditions that might contraindicate study drugs.
* Major surgical procedure, within 28 days prior to study treatment start.
* Pregnant or lactating women.
* Women of childbearing potential with either a positive or no pregnancy test at baseline (NB. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
* Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No